Neurocrine Biosciences
NBIX
122 hedge funds and large institutions have $681M invested in Neurocrine Biosciences in 2013 Q3 according to their latest regulatory filings, with 27 funds opening new positions, 39 increasing their positions, 45 reducing their positions, and 29 closing their positions.
52% more call options, than puts
Call options by funds: $15.3M | Put options by funds: $10.1M
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
7% less first-time investments, than exits
New positions opened: 27 | Existing positions closed: 29
3% less funds holding
Funds holding: 126 → 122 (-4)
13% less capital invested
Capital invested by funds: $778M → $681M (-$97.5M)
13% less repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 45
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$29.5M |
| 2 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
+$26.8M |
| 3 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
+$13.8M |
| 4 |
State Street
Boston,
Massachusetts
|
+$10.9M |
| 5 |
MG
Meditor Group
Hamilton,
Bermuda
|
+$10.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
-$15M |
| 2 |
PA
Perceptive Advisors
New York
|
-$11.1M |
| 3 |
SCA
SAC Capital Advisors
Stamford,
Connecticut
|
-$9.57M |
| 4 |
VM
VHCP Management
New York
|
-$9.53M |
| 5 |
PC
Polar Capital
London,
United Kingdom
|
-$9.37M |
NBIX Hedge Fund Activity: Q3 2013 in Review
122 of the 3,096 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q3 2013, worth a combined $681M — down 13% from $778M a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of NBIX and 27 opened new positions — a net loss of 2 holders — while 45 trimmed existing stakes and 39 added.
The largest buyer was T. Rowe Price Associates, adding an estimated $29.5M. The largest seller was Loomis, Sayles & Company, exiting entirely with an estimated $15M sold.
- 122 institutional investors held Neurocrine Biosciences (NBIX) as of Q3 2013, down from 126 in Q2 2013.
- Funds reported $681M of Neurocrine Biosciences stock for Q3 2013, down 13% quarter-over-quarter.
- 27 funds opened new Neurocrine Biosciences positions in Q3 2013 and 29 closed out, a net change of -2 holders.
- The largest Neurocrine Biosciences buyer in Q3 2013 was T. Rowe Price Associates, an estimated $29.5M added.
- The largest Neurocrine Biosciences seller in Q3 2013 was Loomis, Sayles & Company, an estimated $15M sold.
Based on aggregated 13F filings for Q3 2013.